Elutia Inc. – NASDAQ:ELUT

Elutia stock price today

$2.02
-1.92
-48.73%
Financial Health
0
1
2
3
4
5
6
7
8
9

Elutia stock price monthly change

-10.46%
month

Elutia stock price quarterly change

-10.46%
quarter

Elutia key metrics

Market Cap
151.20M
Enterprise value
N/A
P/E
N/A
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
N/A
PEG ratio
N/A
EPS
N/A
Revenue
N/A
EBITDA
N/A
Income
N/A
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Elutia stock price history

Elutia stock forecast

Elutia financial statements

Elutia Inc. (NASDAQ:ELUT): Profit margin
2020 42.68M -21.82M -51.13%
2023 24.74M -37.65M -152.18%
Elutia Inc. (NASDAQ:ELUT): Debt to assets
2023 43428000 82.02M 188.88%
Elutia Inc. (NASDAQ:ELUT): Cash Flow
2023 -21.76M 14.20M 9.84M

Elutia alternative data

Elutia Inc. (NASDAQ:ELUT): Employee count
Dec 2024 54

Elutia other data

Elutia Inc. (NASDAQ:ELUT): Insider trades (number of shares)
Period Buy Sel
Mar 2023 140000 0
Transaction Date Insider Security Shares Price per share Total value Source
Option
FERGUSON MATTHEW officer: CHIEF FINANCIAL OFFICER
Class A Common Stock 12,500 N/A N/A
Option
FERGUSON MATTHEW officer: CHIEF FINANCIAL OFFICER
Restricted Stock Units 12,500 N/A N/A
Option
MILLS C RANDAL director, officer: PRESIDENT AN..
Restricted Stock Units 27,083 N/A N/A
Option
MILLS C RANDAL director, officer: PRESIDENT AN..
Class A Common Stock 27,083 N/A N/A
Option
WILLIAMS MICHELLE LEROUX officer: CHIEF SCIENTIFIC OFFICER
Restricted Stock Units 12,500 N/A N/A
Option
WILLIAMS MICHELLE LEROUX officer: CHIEF SCIENTIFIC OFFICER
Class A Common Stock 12,500 N/A N/A
Option
WILLIAMS MICHELLE LEROUX officer: CHIEF SCIENTIFIC OFFICER
Restricted Stock Units 12,500 N/A N/A
Option
WILLIAMS MICHELLE LEROUX officer: CHIEF SCIENTIFIC OFFICER
Class A Common Stock 12,500 N/A N/A
Option
MILLS C RANDAL director, officer: PRESIDENT AN..
Restricted Stock Units 27,084 N/A N/A
Option
MILLS C RANDAL director, officer: PRESIDENT AN..
Class A Common Stock 27,084 N/A N/A
  • What's the price of Elutia stock today?

    One share of Elutia stock can currently be purchased for approximately $2.02.

  • When is Elutia's next earnings date?

    Unfortunately, Elutia's (ELUT) next earnings date is currently unknown.

  • Does Elutia pay dividends?

    No, Elutia does not pay dividends.

  • How much money does Elutia make?

    Elutia has a market capitalization of 151.20M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 42.02% to 24.75M US dollars.

  • What is Elutia's stock symbol?

    Elutia Inc. is traded on the NASDAQ under the ticker symbol "ELUT".

  • What is Elutia's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Elutia?

    Shares of Elutia can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Elutia have?

    As Dec 2024, Elutia employs 54 workers.

  • When Elutia went public?

    Elutia Inc. is publicly traded company for more then 4 years since IPO on 8 Oct 2020.

  • What is Elutia's official website?

    The official website for Elutia is elutia.com.

  • Where are Elutia's headquarters?

    Elutia is headquartered at 12510 Prosperity Drive, Silver Spring, MD.

  • How can i contact Elutia?

    Elutia's mailing address is 12510 Prosperity Drive, Silver Spring, MD and company can be reached via phone at +240 2471170.

Elutia company profile:

Elutia Inc.

elutia.com
Exchange:

NASDAQ

Full time employees:

54

Industry:

Biotechnology

Sector:

Healthcare

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

12510 Prosperity Drive
Silver Spring, MD 20904

CIK: 0001708527
ISIN: US05479K1060
: